Mirum SVP sells 4,732 shares after RSU vesting

Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share. On March 16, 2026, she sold 4,732 common shares at 91.9779 per share to cover tax withholding obligations related to this vesting, and held 8,429 shares afterward. Footnotes state the performance restricted stock units vest in stages over March 15, 2025–2027.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 4,732 shs ($435K)

Approx. gross sale proceeds $435K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	4,732	$91.9779	$435K
Exercise	Performance Restricted Stock Units	2,658	$0.00	$0.00
Exercise	Performance Restricted Stock Units	6,000	$0.00	$0.00
Exercise	Common Stock	2,658	$0.00	$0.00
Exercise	Common Stock	6,000	$0.00	$0.00

Holdings After Transaction: Performance Restricted Stock Units — 3,000 contracts (Direct); Common Stock — 8,429 shares (Direct)

Footnotes (4)

1. F1. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
3. F3. The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.
4. F4. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

FAQ

What did Mirum Pharmaceuticals (MIRM) executive Jolanda Howe report in this Form 4?

Jolanda Howe reported exercising performance restricted stock units into 8,658 Mirum Pharmaceuticals common shares and selling 4,732 shares. The sale was described as covering tax withholding obligations tied to the vesting of those performance-based equity awards.

How many Mirum Pharmaceuticals (MIRM) shares did Jolanda Howe sell and at what price?

She sold 4,732 shares of Mirum Pharmaceuticals common stock at a price of 91.9779 per share. The filing notes these shares were sold to satisfy tax withholding obligations related to the vesting of performance restricted stock units.

How many Mirum Pharmaceuticals (MIRM) shares does Jolanda Howe hold after the reported transactions?

After the reported transactions, Jolanda Howe directly holds 8,429 shares of Mirum Pharmaceuticals common stock. This figure reflects the net position following the exercise of performance restricted stock units and the sale of 4,732 shares for tax withholding.

What type of derivative securities did Jolanda Howe exercise at Mirum Pharmaceuticals (MIRM)?

She exercised performance restricted stock units at Mirum Pharmaceuticals, which are derivative awards where each unit represents a contingent right to receive one common share. The filing shows 8,658 units converting into 8,658 shares of common stock.

How do the performance restricted stock units for Mirum Pharmaceuticals (MIRM) vest for Jolanda Howe?

Footnotes state the performance restricted stock units vest in tranches. For the reported grants, two-thirds of the shares vest on March 15 of one year and one-third on March 15 of the following year, with schedules running through 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 07:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		2,658	A	(1)	7,161	D
Common Stock	03/15/2026		M		6,000	A	(1)	13,161	D
Common Stock	03/16/2026		S(2)		4,732	D	$91.9779	8,429	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Restricted Stock Units	(1)	03/15/2026		M			2,658	(3)	(3)	Common Stock	2,658	$0	0	D
Performance Restricted Stock Units	(1)	03/15/2026		M			6,000	(4)	(4)	Common Stock	6,000	$0	3,000	D

Explanation of Responses:

1. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.

3. The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.

4. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.